Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

April 27, 2023

Komal Jhaveri, MD, FACP, discusses findings from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial (NCT05216432) of the PI3Kα inhibitor RLY-2608 in patients with PIK3CA-mutant advanced breast cancer.

April 21, 2023

The combination of batiraxcept and cabozantinib is safe and generated early evidence of efficacy in pretreated patients with advanced or metastatic clear cell renal cell carcinoma.

April 17, 2023

The RAF dimer inhibitor BGB-3245 generated early efficacy signals with a tolerable safety profile in patients with advanced or refractory solid tumors harboring MAPK pathway mutations.

April 17, 2023

Patients with African ancestry with colorectal cancer have fewer actionable gene mutations than those with European ancestry, leading to fewer targeted treatment options in this population.

April 13, 2023

Despite a high-profile clinical disappointment, the TIGIT immune checkpoint remains an important target for anticancer therapy, with research programs testing novel agents moving forward in non–small cell lung cancer and a range of other tumor types.

April 10, 2023

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.

April 07, 2023

Zachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.

April 06, 2023

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.

April 04, 2023

Ryan Kahn, MD, MHS, discusses the investigation of Newcastle disease virus encoded with interleukin 12 in ovarian cancer.

March 30, 2023

Beryl Manning-Geist, MD, discusses findings from a study evaluating the effects of primary treatment modality on secondary cytoreduction outcomes in patients with high-grade ovarian cancer.

March 16, 2023

Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.

March 15, 2023

A new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.

March 14, 2023

James Harding, MD, discusses the management of immune-related adverse effects in patients with advanced biliary tract cancer.

March 14, 2023

Raajit K. Rampal, MD, PhD, discusses how the role of JAK inhibitors will continue to evolve in the treatment of patients with myelofibrosis.

March 11, 2023

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

March 09, 2023

Pallawi Torka, MD, discusses the BTK inhibitors available for treatment of patients with relapsed/refractory mantle cell lymphoma.

March 08, 2023

Pallawi Torka, MD, discusses the clinical implications of the FDA approval of pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma.

March 06, 2023

Sergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

March 06, 2023

Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.

March 03, 2023

The advent of antibody-drug conjugates has placed a renewed focus on the lesser thought of HER2 classifications of IHC 1+ and 0.